A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted results- Registry ID
- NCT06226883
- Phase
- Phase 2
- Recruitment
- Enrolling participants
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- Design
- Randomized
- Comparator
- Group 1 (Part A); Group 2 (Part A); Group 3 (Part A); Group 4 (Part B); Group 5 (Part B); Group 6 (Part B)
- Planned enrollment
- 385
- Endpoint
- Proportion of participants with endoscopic response at Week 14 as determined using the Simple Endoscopic Score-CD (SES-CD)
Study ages: 18 Years to 85 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Australia, Austria, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Estonia, France, Georgia, Germany, Hungary, India, Italy, Japan, Kazakhstan, Latvia, Mexico, Moldova, Poland, Romania, Serbia, Slovakia, Spain, Taiwan, United States.
Sites marked recruiting: Australia, Austria, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Estonia, France, Georgia, Germany, Hungary, India, Italy, Japan, Kazakhstan, Latvia, Mexico, Poland, Romania, Serbia, Slovakia, Spain, Taiwan, United States. Check the original registry record for locations and study-team contacts; overall recruiting status does not guarantee a local place.
Primary data collection: Sep 2028 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1